nowaday
vaccin
consid
econom
strategi
handl
variou
diseas
microbi
infect
autoimmun
relev
disord
even
certain
type
cancer
annual
million
human
live
save
lethal
infect
result
prompt
immun
vaccin
also
play
role
conquer
lifethreaten
diseas
autoimmun
disord
allerg
reaction
notabl
past
year
refractori
cancer
also
includ
scope
vaccin
target
subject
immunotherapi
achiev
great
therapeut
effect
certain
patient
thank
advanc
made
immunolog
biotechnolog
relev
field
howev
today
still
long
list
infect
urgent
need
effect
vaccin
unfortun
may
exist
yet
least
forese
futur
reason
mani
microbi
pathogen
hiv
human
immunodefici
viru
hcv
hepat
c
viru
hsv
herp
simplex
viru
show
elus
everchang
immunogen
featur
appear
continu
challeng
current
avail
vaccin
strategi
dismantl
varieti
potenti
arsen
meanwhil
pathogen
ebola
viru
sar
viru
sever
acut
respiratori
syndrom
viru
may
emerg
abruptli
uncertain
place
make
ravag
peopl
disappear
effect
strategi
drawn
trial
battl
leav
even
trace
hint
develop
efficaci
product
abl
tame
nevertheless
past
decad
wit
rang
lethal
infecti
pathogen
smallpox
hpv
hbv
vzv
varicella
zoster
viru
nearli
conquer
newli
develop
medic
includ
especi
vaccin
particular
past
year
immunotherapi
establish
promis
strategi
treat
refractori
diseas
includ
certain
lethal
cancer
inherit
diseas
anaphylaxi
disord
autoimmun
rheumatoid
arthriti
multipl
sclerosi
lupu
though
still
tortur
numer
patient
also
wane
intens
mortal
due
kind
vaccin
treatment
vaccin
well
immunotherapi
act
battl
diseas
make
use
host
immun
system
activ
antigen
compon
call
antigen
diseasecaus
subject
call
pathogen
set
immun
capabl
eras
pathogen
bear
ident
antigen
ag
process
involv
immun
establish
present
principl
develop
vaccin
howev
made
differ
formul
display
divers
dosag
form
convent
vaccin
made
whole
microb
inactiv
attenu
usual
possess
potent
power
induc
agspecif
immunorespons
host
also
link
safeti
issu
result
mainli
revers
administ
strain
virul
mutant
support
outcom
gene
sequenc
vaccin
suffer
notabl
past
decad
great
achiev
immunolog
cell
biolog
well
bioengin
technolog
allow
rapid
identif
purif
novel
ag
refin
ag
capabl
formul
definit
ingredi
constitut
subunit
vaccin
elicit
immun
accur
target
highli
match
object
maintain
excel
safeti
profil
thu
subunit
vaccin
employ
fight
variou
diseas
includ
infect
also
intract
autoimmun
malici
cancer
compar
classic
vaccin
subunit
vaccin
possess
mani
distinct
benefit
high
safeti
need
danger
microorgan
product
redund
compon
relev
reactogen
divers
therapi
scope
includ
infect
autoimmun
cancer
feasibl
engag
sever
peptid
epitop
one
product
target
differ
subtyp
life
cycl
stage
pathogen
howev
subunit
vaccin
made
highli
purifi
ag
often
show
poor
immunogen
therefor
hardli
induc
effect
immunorespons
absenc
adjuv
substanc
includ
formul
enabl
vaccin
effici
elicit
agspecif
immun
high
level
long
durat
ensur
reliabl
antiag
protect
moreov
subunit
vaccin
lack
microbi
constitu
includ
especi
fact
adjuvanticitybear
substanc
conserv
display
microb
surfac
manifest
certain
distinct
structur
featur
defin
pathogendamagedangerassoci
molecular
pattern
pampsdamp
pamp
damp
strongli
activ
innat
immunorespons
bind
stimul
correspond
pattern
recognit
receptor
prr
includ
mainli
tlr
tolllik
receptor
clr
ctype
lectin
receptor
rlr
retinoicacidinduc
geneilik
receptor
nlr
nucleotidebind
oligomer
domainlik
receptor
newli
identifi
cga
cgmpamp
synthas
cytosol
dna
sensor
prr
respons
detect
pathogen
microb
evolutionarili
express
immun
cell
especi
profession
apc
antigen
present
cell
includ
mainli
dc
dendrit
cell
mp
macrophag
due
lack
pampsdamp
subunit
vaccin
usual
low
capac
activ
innat
immun
system
precursor
sponsor
respons
initi
adapt
immun
system
set
antiag
immun
therefor
conquer
drawback
subunit
vaccin
often
addit
combin
adjuv
incorpor
carrier
enhanc
immunostimulatori
effect
notabl
present
subunit
vaccin
frequent
constitut
variou
nanocarri
liposom
emuls
cochleat
vlp
viruslik
particl
polymer
inorgan
nanoparticl
np
incorpor
divers
adjuv
adjuvanticitybear
substanc
differ
prra
prr
agonist
squalen
saponin
well
insolubl
aluminium
salt
alum
thu
form
vaccin
adjuvantdeliveri
system
vad
enhanc
efficaci
fact
earli
signific
enhanc
efficaci
subunit
vaccin
one
compos
diphtheria
toxoid
success
achiev
glenni
colleagu
precipit
ag
onto
alum
ever
sinc
wide
adopt
effici
strategi
improv
vaccin
effect
result
alum
employ
classic
vad
produc
variou
type
vaccin
clinic
prophylaxi
rang
pathogen
today
still
given
million
peopl
year
actual
vad
construct
nanocarri
prove
abl
fulfil
multipl
function
includ
protect
ag
prematur
degrad
maintain
ingredi
prolong
releas
target
cargo
profession
apc
boost
vaccin
immunostimulatori
effect
thu
make
full
use
bioactiv
agent
save
dose
among
differ
categori
nanocarri
liposom
sinc
discoveri
fervent
exploit
construct
dd
drug
deliveri
system
vad
owe
mani
advantag
excel
biocompat
divers
load
mode
big
load
capac
easi
prepar
surfac
modif
gener
desir
function
also
vad
liposom
suitabl
make
vaccin
adapt
variou
administr
rout
intramuscular
subcutan
inject
oral
uptak
intranas
topic
way
moreov
liposom
long
confirm
intrins
adjuvant
unlik
adjuv
show
minim
reactogen
therefor
rare
caus
hypersensitivityassoci
reaction
immun
subject
addit
argu
liposom
alway
play
well
role
adjuv
regardless
ag
load
mode
entrap
within
attach
onto
even
simpli
admix
vesicl
thu
greatli
simplifi
product
manufactur
procedur
owe
omit
tediou
step
remov
free
ag
also
liposom
extens
explor
combin
varieti
function
molecul
one
bear
pamp
damp
featur
abl
bind
certain
prr
one
match
receptor
express
apc
facilit
apc
uptak
vaccin
notabl
decad
develop
sever
type
liposom
design
vad
alreadi
success
employ
make
vaccin
approv
clinic
immun
differ
infect
includ
even
caus
intract
pathogen
malaria
shingl
review
paper
describ
knowledg
signific
liposom
use
vad
includ
principl
immun
design
liposom
vad
featur
properti
liposom
benefici
construct
vad
stateoftheart
advanc
liposom
vad
also
approv
vaccin
manufactur
advanc
liposom
technolog
present
comprehens
refer
liposom
vaccin
modern
vaccin
concept
gradual
establish
sinc
late
eighteenth
centuri
edward
jenner
took
pu
hand
milkmaid
cowpox
scratch
arm
recipi
thu
success
protect
smallpox
infect
jenner
preliminarili
laid
primari
principl
develop
modern
vaccin
contain
antigen
ag
administr
trigger
host
immun
system
set
defens
network
agexhibit
pathogen
support
basi
establish
defenc
lie
vertebr
higher
organ
includ
human
be
complex
immun
system
well
form
long
time
surviv
evolut
pressur
pathogen
thu
consist
sever
order
differenti
structur
composit
includ
lymphoid
organ
tissu
divers
immun
cell
variou
chemokin
cytokin
orchestr
engend
protect
immun
case
danger
signal
stimul
spark
vaccin
pathogen
immun
system
function
motiv
compon
act
togeth
influenc
form
throughout
bodi
solid
defenc
pathogen
one
main
defens
compon
immun
system
possess
abil
discern
numer
contact
subject
abnorm
pathogen
detriment
factor
bodi
interact
subject
surfac
structur
structur
pathogen
usual
compos
glycoprotein
may
show
depend
type
speci
certain
uniqu
conserv
featur
fall
within
rang
antigen
pampsdamp
evolutionarili
defin
host
immun
system
result
long
term
fight
repeatedli
occur
opposit
side
host
pathogen
gradual
immun
system
build
power
defenc
detriment
invad
includ
variou
infecti
microorgan
bacteria
virus
fungi
parasit
even
cancer
neoplasm
aris
bodi
typic
ag
carri
vaccinepathogen
enter
vertebr
host
first
time
via
breach
skin
mucos
barrier
immedi
recogn
intern
tissueresid
apc
fig
mainli
dc
mp
also
langerhan
cell
uniqu
type
mp
inhabit
stratifi
squamou
epithelium
skin
variou
type
mucos
tissu
ie
stratifi
epitheliumcov
mucosa
display
remark
mixtur
properti
mp
eg
selfmaintain
local
dc
eg
homeostat
migrat
drain
lymph
node
present
ag
lymphocyt
also
fraction
ag
vaccinepathogen
may
traffic
directli
drain
lymph
node
dln
wherein
captur
endocytos
within
apc
includ
dc
mp
follicular
b
cell
fbc
intern
ag
process
apc
smaller
piec
includ
epitop
antigen
determin
load
onto
mhc
major
histocompat
complex
molecul
togeth
display
cell
surfac
present
lymphocyt
take
place
within
dln
fig
case
direct
blood
entranc
caus
eg
inject
vaccin
blood
infus
contamin
extern
bleed
insect
bite
ag
rapidli
filter
captur
splenic
apc
also
includ
mainli
mp
dc
fbc
spleen
anatom
organ
white
pulp
resembl
ln
particularli
regard
special
compart
b
cell
cell
popul
spleen
numer
ln
togeth
present
main
arena
innat
adapt
immunorespons
proceed
establish
antiag
immun
ag
uptak
peripher
apc
mainli
dc
also
langerhan
cell
activ
migrat
dln
process
endocytos
cargo
fragment
includ
ag
epitop
subsequ
bind
either
mhci
endogen
ag
eg
deriv
cellular
wast
viral
protein
mhcii
molecul
exogen
ag
eg
deliv
vaccin
display
apc
surfac
form
mhciiiag
epitop
fig
dlnspleen
mhciiag
epitop
display
apc
interact
divers
tcr
cell
receptor
cell
thu
stimul
differenti
mainli
depend
cytokin
either
cell
type
helper
cell
usual
costimul
cell
usual
costimul
secret
collect
cytokin
trigger
two
downstream
respons
one
downstream
contribut
cellular
respons
wherebi
apc
mhciag
epitop
bind
tcr
cell
addit
costimul
usual
secret
mainli
activ
cell
turn
via
differenti
agspecif
ctl
cytotox
lymphocyt
memori
ctl
mctl
fig
ctl
may
migrat
circul
system
peripher
tissu
abl
recogn
bind
via
tcr
ident
mhciag
epitop
present
encount
pathogenhidden
diseas
cell
problemat
cell
target
ctl
induc
undergo
seri
intracellular
caspas
cascad
follow
apoptosi
lysi
due
receiv
cytokin
chemic
perforin
granzym
cytotoxin
granulysin
secret
bound
ctl
lead
dump
pathogen
full
erad
mctl
respons
provid
longterm
protect
host
sinc
surviv
long
time
lyse
emerg
infect
cell
display
mhciagepitop
ident
initi
trigger
thu
eras
relev
pathogen
fig
downstream
account
thymu
depend
humor
respons
wherebi
vivo
ag
partial
taken
apc
present
mhciiagepitop
thu
induc
product
cell
meanwhil
partial
ag
traffic
dln
wherein
may
captur
lnresid
dc
mp
either
surfac
present
activ
cell
transit
fdc
follicular
dc
fdc
abl
retain
ag
long
time
nondegrad
form
period
display
allow
ag
bind
highli
divers
bcr
b
cell
receptor
otherwis
ag
arriv
dln
may
directli
enter
follicl
directli
bind
bcr
known
signal
subsequ
bcrag
endocytos
process
follicular
b
cell
fbc
present
mhciiagepitop
border
tcell
zone
b
cell
follicl
ln
recogn
bound
tcr
differenti
cell
process
known
cognat
tb
cell
cooper
signal
meanwhil
b
cell
bound
costimul
ligand
differenti
cell
thu
fulli
activ
secret
cytokin
signal
trigger
b
cell
seed
germin
center
differenti
prolifer
plasma
cell
includ
shortliv
longliv
plasma
cell
well
memori
b
cell
mbc
plasma
cell
produc
agspecif
ab
abl
neutral
pathogenet
subject
noninfecti
organ
prior
settlement
host
fig
notabl
longterm
product
ab
may
maintain
combin
shortliv
plasma
cell
usual
life
day
longliv
plasma
cell
pc
acquir
longliv
properti
migrat
surviv
nich
within
bone
marrow
fig
wherein
receiv
surviv
factor
april
proliferationinduc
ligand
thu
may
exist
even
lifetim
host
depend
partial
stimulatori
ag
altern
high
level
ab
may
rapidli
produc
result
prompt
prolifer
differenti
mbc
shortliv
plasma
cell
upon
reencount
ident
ag
usual
carri
pathogen
fig
notabl
certain
type
ag
bear
multipl
repeat
epitop
bacteri
cell
wall
polysaccharid
glycolipid
nucleic
acid
bind
multipl
number
mediat
bcr
first
undergo
cluster
act
signal
directli
activ
b
cell
b
cell
induc
independ
cell
differenti
plasma
cell
process
known
tindepend
b
cell
activ
memori
b
cell
produc
ab
low
affin
mainli
igm
immunosuppress
sialyl
igg
may
favour
antipathogen
immun
gener
tdepend
process
abl
imprint
immun
system
ag
featur
establish
immun
memori
mark
form
longliv
memori
cell
includ
mtc
possibl
deriv
effector
counterpart
longliv
memori
b
cell
ln
spleen
peripher
tissu
gener
immun
memori
thought
import
consequ
vaccin
enabl
pathogenexperienc
host
possess
abil
rapidli
initi
respons
encount
pathogen
bear
ident
ag
thu
engend
prompt
immun
remov
invad
acquir
compet
experi
host
immun
system
defeat
pathogen
annot
basic
concept
immun
main
principl
underli
vaccin
deep
understand
undoubtedli
acceler
develop
novel
vaccin
well
vad
cope
aggress
pathogen
howev
present
though
thought
vaccin
vad
design
aim
stimul
robust
respons
gener
substanti
number
effector
cell
memori
cell
popul
might
expect
aris
best
condit
effici
promot
format
memori
immun
cell
remain
still
fulli
defin
earli
vaccin
develop
defend
pathogen
infect
thu
simpli
made
whole
organ
inactiv
attenu
reduc
inher
virul
pathogen
maintain
still
abil
activ
host
immun
system
administr
establish
efficaci
immun
match
microb
usual
live
attenu
pathogenbas
vaccin
possess
capabl
elicit
robust
longlast
immun
recipi
howev
also
potenti
caus
detriment
infect
recipi
result
occurr
unpredict
mutat
engin
organ
exampl
recent
year
immun
oral
polio
vaccin
consist
live
attenu
poliovirus
astonishingli
found
gene
sequenc
caus
sever
pandem
polio
due
revers
vaccin
strain
neurovirul
transmiss
state
wild
poliovirus
comparison
vaccin
made
inactiv
microorgan
rel
safe
stimul
rather
weak
even
targetdevi
immunorespons
result
inactiv
process
may
alter
sequenc
authent
ag
comprehens
compon
like
induc
irrelev
immunorespons
even
trigger
unwant
inflamm
due
exist
reactogen
overcom
weak
whole
microbebas
product
present
vaccin
often
formul
use
purifi
ag
auxiliari
ingredi
includ
socal
adjuv
markedli
enhanc
potenc
vaccin
trigger
innat
immunorespons
frequent
includ
adjuv
human
vaccin
alum
aluminium
salt
first
use
vaccin
adjuv
earli
glenni
colleagu
still
wide
use
variou
vaccin
numer
infect
contribut
greatli
human
health
though
alum
vaccin
may
caus
stimulatori
inflamm
give
rise
certain
advers
effect
administr
gener
accept
safeti
profil
possess
abil
enhanc
efficaci
mani
vaccin
correspond
pathogen
fact
mechan
underli
adjuv
action
relev
prr
stimul
remain
mostli
still
elus
secret
full
unveil
undoubtedli
pave
way
discov
novel
adjuv
present
thought
vaccin
adjuv
eg
alum
may
act
combin
variou
mechan
form
depot
recruit
immun
cell
enhanc
ag
uptak
present
induc
product
cytokin
chemokin
promot
ag
apc
traffic
dln
larg
adjuv
improv
immunorespons
case
result
recruit
immun
cell
dc
mp
neutrophil
vaccin
site
facilit
apc
uptak
ag
activ
innat
immun
cell
neutrophil
natur
killer
cell
nkc
especi
profession
apc
mainli
dc
mp
fig
aspect
promot
releas
specif
myriad
cytokin
chemokin
promot
gener
special
lymphocyt
subset
cell
also
present
ag
mhci
andor
ii
mode
result
enhanc
humor
andor
cellular
immun
pathogen
fig
also
argu
classic
adjuv
exert
shortliv
effect
adapt
immunorespons
may
aris
influenc
specif
collect
cytokin
chemokin
releas
immunocyt
stimul
adjuvantactiv
apc
short
life
safeti
concern
convent
vaccin
promot
scientist
develop
novel
subunit
vaccin
base
whole
microorgan
antigen
part
protein
dna
rna
synthet
carriervector
ag
howev
lack
compon
pathogen
may
play
role
protect
antigen
also
act
type
pampdamp
often
make
subunit
vaccin
vulner
environment
damag
ineffect
trigger
immunorespons
toward
ag
enhanc
potenc
subunit
vaccin
research
develop
variou
type
particul
carrier
liposom
cochleat
virosom
emuls
lipid
polymer
np
construct
manner
mimick
structur
pathogen
organ
carri
protect
deliv
vaccin
thu
promot
immunostimulatori
activ
also
particul
carrier
often
addit
incorpor
function
molecul
tlra
tolllik
receptor
agonistsligand
clra
ctype
lectin
receptor
agonistligand
nlra
nodlik
receptor
agonistsligand
saponin
squalen
deriv
variou
environment
stimulussensit
molecul
expand
function
carrier
play
role
adjuv
boost
immunostimulatori
effect
also
deliveri
vehicl
target
immunocyt
well
sustain
signaltrigg
releas
engend
multifunct
vaccin
adjuvantdeliveri
system
vad
best
illumin
concept
vad
may
perhap
present
cite
fda
food
drug
administr
usa
approv
novel
adjuv
entiti
nanoemulsionsqualenebas
aluminium
use
sever
vaccin
serv
adjuv
vehicl
deliv
bioactiv
ingredi
develop
vaccin
suitabl
adjuv
play
crucial
role
enhanc
immunostimulatori
effect
may
well
combin
ag
appropri
formul
carrier
thu
formul
vaccin
better
feasibl
largescal
manufactur
abl
deliv
compon
apc
ignit
launch
wave
first
innat
subsequ
adapt
immunorespons
magnitud
qualiti
breadth
well
persist
suffici
establish
efficaci
antipathogen
immun
therefor
success
vaccin
may
consist
three
key
compon
effect
ag
robust
adjuv
effici
formul
carrier
abl
deliv
ingredi
apc
even
intracellular
organel
least
appropri
site
ln
mucosa
whilst
vaccin
carrier
develop
variou
micronanoparticl
differ
type
liposom
convent
liposom
interbilay
crosslink
multilamellar
vesicl
icmv
solid
core
liposom
bear
uniqu
structur
properti
promin
repres
suitabl
vad
liposom
phospholipid
bilayerenclos
sphere
form
via
selfassembl
water
drive
forc
hydrophob
liposom
first
discov
earli
bangham
et
al
use
electron
microscop
later
coin
name
liposom
sessa
weissmann
liposom
uniqu
architectur
confin
propos
israelachvili
mitchel
middl
molecular
shape
amphiphil
phospholipid
critic
pack
paramet
cpp
rang
cpp
defin
equat
cpp
va
l
c
v
l
c
respect
volum
length
lipophil
chain
crosssect
area
hydrophil
core
phospholipid
express
per
molecul
aggreg
amphiphil
molecul
cpp
valu
fall
rang
assembl
shape
shown
fig
gener
liposom
may
made
differ
type
amphiphil
phospholipid
pc
phosphatidylcholin
ps
phosphatidylserin
sm
sphingomyelin
may
also
combin
lipid
cho
cholesterol
membran
stabil
neg
posit
charg
lipid
modul
liposom
structur
surfac
properti
thu
form
suitabl
carrier
use
dd
drug
deliveri
system
vad
materi
frequent
use
prepar
liposom
shown
molecular
structur
fig
notabl
ambient
temperatur
liposom
display
bilay
membran
fluid
rigid
fluiditi
state
determin
phospholipid
categori
hydrocarbon
chain
length
usual
longer
well
satur
fig
paramet
togeth
locat
unsatur
carbon
bond
remark
influenc
van
de
waal
forc
interact
among
adjac
chain
phospholipid
thu
govern
membran
manifest
correspond
fluiditi
liposom
membran
consist
type
phospholipid
show
specif
gel
liquid
crystallin
phase
transit
temperatur
c
howev
may
blur
mixtur
lipid
egg
pc
soy
pc
combin
cho
use
thu
liposom
made
phospholipid
c
ambient
temperatur
membran
correspondingli
rigid
gel
fluid
liquid
crystallin
phase
howev
liposom
made
phospholipid
c
equival
ambient
temperatur
membran
manifest
maxim
permeabl
may
abruptli
releas
load
cargo
phenomenon
sometim
employ
engin
temperaturesensit
carrier
room
temperatur
whilst
liposom
lipid
long
satur
hydrocarbon
chain
high
c
tend
form
rigid
order
bilay
structur
may
gel
phase
liposom
lipid
short
unsatur
chain
low
c
gener
fluid
disorganis
bilay
may
liquidcrystallin
phase
fig
interestingli
incorpor
cho
may
significantli
influenc
fluiditi
membran
high
concentr
chopc
mol
may
smear
gelliquid
crystallin
transit
phenomenon
liposom
particularli
cho
may
remark
decreas
permeabl
membran
thu
often
employ
prevent
leakag
liposom
especi
lyophil
elev
temperatur
remot
drug
load
involv
far
stabil
concern
surfac
pegyl
modif
peg
anoth
effect
way
enhanc
liposom
qualiti
engend
vesicl
steric
stabil
effect
pegyl
prevent
liposom
coagul
fusion
also
might
allow
liposom
avoid
bound
plasma
protein
bound
certain
specif
type
plasma
protein
recent
surprisingli
report
abl
enorm
prolong
np
nanoparticl
circul
time
vivo
thu
gener
socal
stealth
effect
liposom
addit
liposom
enhanc
stabil
charg
cation
anion
lipid
gener
repuls
electrostat
forc
repel
avoid
aggreg
also
freezedri
liposom
presenc
sugar
lyoprotect
form
dri
cake
fix
individu
liposom
solid
matrix
provid
feasibl
strategi
increas
product
stabil
high
enough
meet
clinic
applic
need
recent
sever
novel
type
liposom
ultradeform
vesicl
interbilay
crosslink
multilamellar
vesicl
icmv
solid
core
liposom
engin
vaccin
deliveri
howev
base
convent
liposom
may
design
fit
well
function
vad
thank
distinct
structur
classifi
liposom
three
basic
type
small
unilamellar
vesicl
suv
size
nm
larg
unilamellar
vesicl
luv
size
nm
nm
sphere
singl
phospholipid
bilay
frequent
use
target
dd
vad
micros
multilamellar
vesicl
mlv
numer
concentr
phospholipid
bilay
usual
use
sustain
releas
carrier
micros
multivesicular
liposom
mvl
featur
multipl
waterfil
caviti
separ
continu
connect
lipid
bilay
use
reservoir
long
sustain
releas
fig
sinc
discoveri
bangham
colleagu
liposom
alway
research
focu
varieti
subject
lipid
membran
model
life
origin
narcosi
mechan
especi
dd
vad
due
uniqu
properti
benefici
deliveri
variou
bioactiv
agent
fact
earli
liposom
alreadi
confirm
intrins
adjuvant
gregoriadi
et
al
observ
potent
antibodi
immunorespons
carri
ag
diphtheria
toxoid
vaccin
mice
meanwhil
vaccin
mice
show
inject
site
sign
granuloma
common
side
effect
associ
convent
adjuv
symptom
hypersensit
reaction
receiv
intraven
intrafoot
pad
immun
earli
investig
pave
way
explor
liposom
vad
immedi
follow
numer
studi
reveal
immunostimulatori
activ
liposom
vad
significantli
influenc
physicochem
properti
even
vaccin
rout
liposom
firmli
proven
safe
effect
vad
low
reactogen
abl
carri
multipl
ag
adjuv
function
molecul
prra
even
aluminium
np
enhanc
immuneboost
effect
dictat
immunorespons
toward
andor
pathway
establish
desir
immun
vad
liposom
effici
fulfil
vaccin
deliveri
function
howev
significantli
influenc
mani
liposom
physicochem
attribut
includ
surfac
charg
membran
fluiditi
size
even
agload
mode
entrap
within
associ
surfac
vesicl
confirm
capabl
alter
apc
uptak
process
present
ag
deliv
liposom
surfac
charg
alway
exert
signific
impact
immunostimulatori
function
liposom
key
factor
influenc
ag
load
releas
liposom
stabil
also
affect
via
electrostat
forc
interact
liposom
biolog
compon
immunocyt
even
intracellular
organel
may
oppositelylik
charg
object
cation
liposom
usual
made
addit
incorpor
lipid
quaternari
ammonium
head
group
posit
charg
normal
physiolog
condit
fig
kind
liposom
inject
intraven
mice
may
gener
celldisrupt
haemolysi
effect
render
reduc
practic
applic
vessel
vaccin
contrast
local
administr
cation
liposom
may
caus
tissu
damag
inject
site
lead
releas
endogen
materi
nucleic
acid
may
like
act
damp
activ
immun
cell
form
basi
use
vad
addit
cation
liposom
carri
via
entrap
andor
adsorpt
neg
charg
ag
administr
immedi
releas
due
electrostat
attract
thu
form
depot
effect
recruit
apc
interestingli
apc
usual
neg
charg
therefor
prone
adhes
cation
liposom
thu
subject
acceler
cellular
phagocytosi
make
enhanc
contribut
apc
activ
via
perhap
intracellular
pathway
exampl
cation
liposom
made
ddatdb
ww
dda
dimethyl
dioctadecylammonium
bromid
tdb
success
develop
clinic
trial
vad
deliv
differ
ag
tuberculosi
tb
antigen
hepat
b
viru
hbv
surfac
antigen
hbsag
avail
data
demonstr
cation
liposom
could
safe
induc
robust
cellular
humor
immunorespons
via
either
subcutan
sc
intramuscular
im
vaccin
outcom
strongli
suggest
cation
liposom
promis
vad
abl
effect
deliv
vaccin
elicit
antipathogen
immun
anion
liposom
usual
made
modifi
lipid
fig
neg
charg
normal
physiolog
condit
pg
phosphatidylglycerol
pa
pi
phosphatidylinositol
intuit
anion
surfac
charg
hardli
offer
benefit
deliv
vaccin
apc
given
anion
natur
latter
due
electrostat
repuls
may
repel
neg
charg
particl
access
cellular
uptak
howev
recent
studi
report
presenc
adjuv
gla
glucopyranosyl
lipid
adjuv
anion
liposom
made
chodppcdppg
potent
enhanc
respons
mice
cation
liposom
made
chodppcdptap
case
deliv
mycobacterium
tuberculosi
mtb
ag
moreov
effect
cation
liposom
also
correl
well
vad
protect
mtb
challeng
notabl
mucos
vaccin
anion
neutral
particl
may
advantag
vad
bind
trap
neg
charg
mucu
gel
layer
thu
allow
easili
approach
follicleassoci
epithelia
wherebi
endocytos
cell
also
previou
report
research
confirm
mice
anion
neutral
np
show
higher
affin
peyer
patch
cation
particl
suggest
neg
charg
carrier
may
favour
oral
possibl
mucos
vaccin
design
vad
anion
liposom
often
engin
purpos
incorpor
neg
charg
lipid
special
function
lipid
ps
phosphatidylserin
may
display
special
interact
apc
monophosphoryl
lipid
mpla
adjuv
deriv
acid
hydrolysi
highli
toxic
lipopolysaccharid
lp
prove
abl
safe
trigger
endosom
follow
activ
downstream
trifmedi
cascad
ultim
transcript
factor
exhibit
immunomodulatori
activ
benefici
develop
liposom
vad
moreov
mplamodifi
liposom
suitabl
deliv
varieti
vaccin
among
product
plasmodium
falciparum
hbv
shingl
viru
offici
author
clinic
use
confirm
numer
clinic
case
abl
effici
trigger
immunorespons
human
result
strong
cellular
immun
relat
pathogen
caus
unaccept
side
effect
notabl
among
variou
neg
charg
phospholipid
phosphatidylserin
ps
strikingli
distinguish
other
sinc
cell
membran
compon
strictli
kept
enzym
flippas
inner
layer
normal
cell
membran
howev
apoptosi
mediat
scramblas
act
bidirect
transport
phospholipid
membran
atpindepend
manner
ps
flip
outer
leaflet
instantli
expos
recognit
bind
number
specif
ps
receptor
express
immun
cell
mainli
mp
immatur
dc
immun
cell
subsequ
trigger
devour
time
apoptot
cell
leav
chanc
releas
noxiou
materi
induc
deleteri
autoimmun
reaction
thu
ps
vivo
act
fact
crucial
danger
eat
signal
immun
cell
mainli
apc
provid
probabl
ideal
compon
may
incorpor
liposom
facilit
apc
uptak
carri
ag
sponsor
downstream
immunorespons
note
differ
ps
receptor
differ
immun
cell
apc
upon
ps
ligat
manifest
differ
function
includ
particularli
antiinflammatori
even
tolerogen
effect
effect
one
hand
good
accommod
ps
role
induc
rapid
phagocyt
clearanc
die
cell
silenc
avoid
autoimmun
hand
count
obvious
establish
antipathogen
immun
instanc
previou
work
hoffmann
et
al
show
mice
liposom
made
pspccho
specif
inhibit
immunorespons
postdeliv
ag
cfa
complet
freund
adjuv
prove
decreas
product
dln
cell
agspecif
cell
igg
blood
inhibitori
effect
exert
vivo
activ
ps
receptor
revers
administr
ab
transform
growth
show
increas
express
pstreat
mice
impli
potenti
role
mediat
inhibitori
function
ps
moreov
pscontain
liposom
neither
directli
inhibit
dc
matur
vitro
respons
differ
stimuli
prevent
dc
migrat
dln
vivo
hint
complic
interact
among
variou
immunocyt
involv
suppress
process
sponsor
ps
recent
baluly
group
prepar
factor
viiiload
liposom
pspc
mol
ratio
incub
dc
vitro
caus
increas
secret
immun
mice
due
ps
incorpor
lower
agspecif
ab
respons
also
induc
hyporespons
ag
rechalleng
outcom
suggest
pscontain
liposom
may
function
exert
immun
regulatori
effect
capabl
convert
immunogen
tolerogen
oppos
use
vad
pathogen
howev
recent
work
lui
et
al
show
addit
combinatori
gangliosid
monosial
acid
agload
popc
liposom
remark
increas
antiag
immun
reaction
vaccin
mice
though
insert
ps
alon
carrier
made
minim
contribut
enhanc
also
cauvi
et
al
reveal
murin
model
anion
empti
ps
liposom
trigger
periton
mp
gene
specif
modifi
result
chang
protein
express
periton
cell
includ
increas
secret
sever
chemokin
cytokin
tnfa
consequ
massiv
neutrophil
infiltr
peritoneum
succeed
prove
capabl
neutral
septic
polymicrobi
insult
howev
neutral
pathogen
also
obtain
intraperiton
administr
pg
liposom
suggest
effect
might
caus
neg
charg
properti
phospholipid
possibl
increas
absolut
valu
neg
potenti
mp
plasma
intern
membran
membran
potenti
chang
may
ignit
intracellular
signal
cascad
involv
activ
innat
immunorespons
respons
control
infect
obvious
immunostimulatori
effect
empti
ps
liposom
hardli
directli
translat
agload
vad
function
well
innat
adapt
immun
system
suffici
activ
contrari
neg
report
pscontain
liposom
also
demonstr
differ
research
abl
remark
enhanc
immunostimulatori
potenti
deliv
ag
thu
propos
effect
vad
make
vaccin
pathogen
instanc
arigita
et
al
recent
report
vaccin
deliv
ps
liposom
result
improv
ag
uptak
dc
increas
antibacteri
antibodi
respons
compar
deliv
pg
liposom
cui
group
also
observ
simpli
admix
model
ag
anion
liposom
prepar
dop
dopa
acid
show
compar
even
strong
adjuv
activ
humor
cellular
respons
elicit
stronger
agspecif
antibodi
immun
alum
admix
ag
compar
dopg
liposom
show
weak
adjuvant
howev
research
observ
ps
pa
contain
liposom
encapsul
ag
notic
abil
enhanc
agspecif
immunorespons
evidenc
observ
cocultur
agspecif
clone
cell
presenc
apc
ps
liposom
trigger
agspecif
product
mice
coadministr
agspecif
cell
plu
agload
ps
liposom
could
induc
secret
high
level
serum
splenic
anoth
studi
ps
liposom
demonstr
capabl
promot
apc
uptak
carri
ag
result
liposom
bind
psspecif
receptor
apc
conclus
reinforc
work
chiantia
group
show
antihiv
env
abdecor
ps
liposom
bound
hiv
vlp
viruslik
particl
facilit
mp
intern
liposom
psdepend
manner
summarili
pscontain
liposom
report
differ
group
show
complic
even
conflict
immunostimulatori
activ
inconsist
like
aris
discrep
experiment
formul
deriv
cell
anim
model
howev
without
strong
support
evid
hard
exclud
data
fals
possibl
result
unintent
error
issu
sinc
conflict
result
seem
obtain
experi
close
design
nevertheless
present
remain
uncertain
whether
ps
liposom
develop
practic
vad
enhanc
immunorespons
pathogen
clinic
strategi
suppress
unwant
immunorespons
toward
administ
therapeut
protein
factor
viii
elev
effect
liposom
membran
fluiditi
call
liposom
flexibl
decreas
satur
length
lipid
use
construct
liposom
also
report
complex
impact
activ
liposom
vad
exampl
report
leishmania
donovani
antigenencapsul
liposom
dspc
distearyl
tc
demonstr
improv
adjuv
activ
show
protect
vaccin
mice
subject
lethal
challeng
contrast
agload
liposom
dppc
dipalmitoyl
tc
dmpc
dimyristoyl
tc
show
littl
adjuvant
even
protect
vaccin
mice
challeng
type
pathogen
influenc
liposom
fluiditi
vad
function
thought
relev
interact
liposom
cell
membran
subsequ
liposom
biodistribut
recipi
instanc
demonstr
rigid
liposom
made
dda
dimethyl
dioctadecylammonium
tc
trigger
robust
immun
reaction
fluid
liposom
compos
unsatur
doda
dimethyl
dioleoylammonium
investig
reveal
dda
rigid
liposom
present
larger
amount
ag
inject
site
thu
attract
apc
elev
engend
higher
respons
fluid
doda
liposom
also
doda
liposom
found
readili
releas
ag
inject
site
lead
format
popul
agposit
adjuvantneg
apc
thu
less
activ
howev
earlier
paper
report
hapten
liposom
made
dopc
dioleoyl
tc
dspc
tc
show
low
immunogen
liposom
made
dppc
tc
sphingomyelin
tc
either
intermedi
tc
relev
dppc
dopc
suggest
immunostimulatori
activ
liposom
may
littl
direct
relev
membran
fluiditi
inclus
cho
within
liposom
known
abl
modul
bilay
membran
fluiditi
therefor
wide
employ
formul
liposom
elev
stabil
dd
drug
deliveri
system
howev
term
influenc
cho
immunostimulatori
effect
liposom
vad
conclus
rather
elus
whilst
studi
inclus
cho
liposom
observ
enhanc
immunorespons
investig
also
demonstr
liposom
contain
cho
elev
membran
fluiditi
show
decreas
adjuv
effect
nevertheless
inclus
cho
seem
distinct
impact
immunostimulatori
activ
liposom
vad
although
avail
investig
report
inconsist
result
recent
work
jiskoot
et
al
demonstr
presenc
cho
significantli
contribut
adjuv
effect
influenza
ha
hemagglutinin
load
cation
liposom
compos
edppc
cho
comparison
liposom
contain
cho
edppccho
liposom
facilit
ha
uptak
dc
vitro
enhanc
antiha
immun
mice
howev
cation
liposom
incorpor
cho
exert
moder
impact
immunorespons
trigger
vad
lui
et
al
use
mper
membran
proxim
extern
region
engraft
tetanu
toxoid
tt
ag
popc
matrix
materi
prepar
agload
liposom
vad
hiv
enhanc
efficaci
liposom
incorpor
lipid
includ
ps
phosphatidylserin
combinatori
chosm
sphingomyelin
enrich
hiv
viral
membran
lipid
raft
mper
embed
maintain
peptid
conform
mice
popc
liposom
combin
chosm
induc
significantli
increas
immun
reaction
enhanc
addit
mpla
contrast
insert
ps
alon
popc
liposom
made
contribut
enhanc
immunorespons
outcom
impli
cho
play
role
liposom
vad
embodi
construct
stabl
vad
also
maintain
specif
carrier
structur
display
ag
distinctivenatur
way
thu
make
impact
immun
effect
size
carrier
play
import
role
defin
specif
function
variou
applic
control
size
microor
nanoscal
may
render
carrier
uniqu
properti
entir
differ
macroscop
counter
part
also
size
liposom
signific
impact
immunostimulatori
activ
vad
may
even
dictat
immun
reaction
proceed
toward
pathway
exampl
report
administ
mice
either
subcutan
inject
oral
uptak
smaller
lipid
vesicl
nm
enhanc
develop
respons
wherea
larger
lipid
vesicl
nm
promot
typic
respons
mous
model
h
intrafootpad
inject
whilst
larger
vlp
viruslik
particl
size
nm
mainli
link
dc
linger
inject
site
smaller
vlp
nm
drain
rapidli
dln
wherein
pick
lnresid
immun
cell
howev
previou
work
perri
group
unveil
cation
liposom
ddatdb
ww
differ
size
rang
nm
show
similar
activ
trig
vitro
apc
uptak
vivo
respons
liposom
exhibit
similar
slow
drainag
inject
site
mice
sizedepend
movement
poplit
dln
wherein
larg
vesicl
detect
remark
elev
level
comparison
small
vesicl
result
suggest
contrast
neutral
liposom
cation
liposom
larg
size
may
tend
depot
inject
site
due
bind
cell
tissu
compon
via
electrostat
attract
thu
pick
effici
local
apc
traffick
ln
group
also
found
cation
liposom
larg
size
trigger
high
splenocyt
prolifer
low
secret
posit
charg
vesicl
nm
promot
product
splenocyt
secret
inject
site
favour
respons
cation
liposom
pegyl
passiv
drainag
observ
caus
mous
dln
enhanc
proport
smaller
rather
larger
vesicl
pegyl
small
liposom
exert
lower
depot
effect
induc
deceas
product
increas
comparison
unpegyl
counterpart
suggest
pegyl
cation
liposom
small
size
may
favour
respons
previou
investig
made
intracellular
traffick
ag
deliv
vesicl
compos
glycerolcho
dicetyl
phosphat
result
reveal
ag
carri
vesicl
larg
size
nm
deliv
earli
endosomelik
immatur
phagosom
respons
recruit
agprocess
apparatu
lead
effici
ag
present
contrast
solubl
small
vesicl
nm
carri
ag
rapidli
local
late
endolysosom
wherein
degrad
lead
reduc
agpresent
effici
see
frequent
occurr
lysosom
degrad
ag
useless
piec
invalid
vaccin
research
focus
effort
develop
liposom
multifunct
vad
capabl
deliv
ag
apc
also
render
intracellular
ag
lysosom
escap
lysosom
escap
prove
feasibl
strategi
allow
ag
avoid
lysosom
degrad
process
immunoproteasom
special
proteasom
immunocyt
within
apc
cellular
immunoproteasom
owe
distinct
beta
subunit
special
activ
low
caspaselik
proteolyt
activ
high
chymotrypsinlik
activ
thu
antigen
process
contribut
creat
small
fragment
like
bind
mhci
molecul
present
enhanc
respons
overal
liposom
particul
vaccin
size
nm
preferenti
traffic
dln
may
facilit
pegyl
carrier
particl
molecul
smaller
nm
may
dissemin
tissu
subsequ
enter
system
circul
thu
offer
littl
chanc
lymphat
uptak
larger
particl
nm
like
becom
trap
tissu
creat
depot
effect
inject
site
recruit
pick
apc
matur
travel
dln
sponsor
immunorespons
obvious
vivo
traffic
trend
immunolog
activ
liposom
simultan
influenc
mani
physicochem
properti
includ
size
also
membran
fluiditi
surfac
charg
pegyl
also
mutual
influenc
vad
base
liposom
np
whilst
effici
load
ag
carrier
indispens
objecttarget
deliveri
load
mode
divers
impact
releas
immunostimulatori
activ
ag
lipid
bilayerenclos
structur
liposom
load
ag
sever
mode
adsorpt
linkag
coval
bond
onto
surfac
entrap
interior
intercal
adjac
bilay
particularli
mlv
special
lipid
structur
cochleat
combin
way
recent
perri
group
construct
ddatdb
cation
liposom
vad
load
cation
vesicl
ag
two
mode
adsorpt
surfac
mlv
encapsul
within
drv
dehydrationrehydr
vesicl
research
show
ag
locat
liposom
make
differ
sever
aspect
includ
vaccin
biodistribut
apc
recruit
antibodi
respons
howev
bear
pegyl
mlv
induc
significantli
higher
respons
drv
counterpart
effect
dramat
revers
pegyl
vesicl
drv
formul
promot
higher
respons
previous
group
fabric
agencapsul
adsorb
microspher
poli
lactidecoglycolid
plga
chitosan
dda
show
whilst
ag
bound
carrier
surfac
favour
humor
respons
entrap
ag
like
trigger
n
wang
et
al
journal
control
releas
cellular
respons
contrast
work
jiskoot
et
al
demonstr
adsorpt
influenza
ha
surfac
cation
liposom
compos
dccho
dimethylaminoethan
carbamoyl
cho
dppc
slightli
immunogen
encapsul
ha
within
carrier
prove
induc
ha
inhibit
titer
found
higher
former
latter
recent
rinconrestrepo
et
al
use
ppspeg
poli
propylen
sulfid
poli
ethylen
glycol
engin
two
nanoparticul
system
small
solid
np
nm
ag
link
surfac
via
reduc
disulfid
bond
larg
hollow
polymersom
hpss
nm
ag
encapsul
within
author
prove
small
np
preferenti
augment
ctl
result
instant
cleavag
disulfid
linkag
releas
ag
earli
endosom
thu
render
ag
lysosom
escap
proteasom
process
mhci
present
contrast
hpss
better
activ
cell
enhanc
follicular
helper
fth
cell
respons
activ
follicular
b
lymphocyt
antibodi
product
reason
argu
ag
protect
deliv
hpss
lysosom
wherein
releas
oxid
catalysisdisrupt
hpss
thu
subject
lysosom
process
mhcii
present
author
also
reveal
though
hpss
travel
dln
slower
speed
np
due
increas
interstiti
resist
larger
particl
equival
amount
ag
drain
dln
immun
either
carrier
long
time
point
h
howev
earli
time
point
h
hpss
mainli
retain
lymphat
sinus
allow
ag
sampl
dc
resid
close
ln
cortex
relev
mhcii
present
contrast
np
smoothli
reach
ln
paracort
area
wherein
pick
mid
mhcii
hi
migratori
dc
process
ag
via
proteasom
mhci
present
addit
ag
load
mode
process
may
exert
influenc
bioactiv
ag
sinc
encapsul
ag
within
liposom
may
involv
damag
step
compromis
immunogen
vaccin
contrast
gentl
adsorpt
process
may
accomplish
mix
ingredi
possess
good
chanc
maintain
ag
activ
howev
ag
adsorb
carrier
surfac
may
releas
rel
high
rate
leav
limit
time
window
apc
recruit
may
caus
ineffici
unsynchron
cellular
uptak
ag
adjuv
form
popul
apc
agposit
adjuvantneg
unabl
properli
present
ag
mention
recent
studi
also
report
whilst
encapsul
ag
within
carrier
engend
effici
lysosom
escap
crosspresent
ag
dc
absorpt
carrier
wherea
combin
ag
encapsul
absorpt
ag
plga
np
induc
potent
antiag
immunorespons
mode
alon
due
perhap
adequ
initi
persist
ag
exposur
howev
attract
prove
optim
agload
mode
develop
vad
argument
mix
ag
vad
without
either
encapsul
adsorpt
still
boost
immunorespons
exemplifi
numer
outcom
clinic
preclin
studi
exampl
mention
work
cui
group
prove
anion
liposom
also
display
robust
adjuv
activ
simpli
admix
ag
fact
approv
vaccin
base
vad
base
emuls
base
liposom
base
liposom
numer
alumadjuv
vaccin
mostli
develop
simpl
admix
ag
vad
notabl
aluminiumbas
vadss
mode
ag
load
may
repres
except
given
upon
admix
ag
may
strongli
adsorb
onto
aluminium
particl
like
chemic
alep
bond
aluminium
phosphoru
group
often
enrich
variou
protein
ag
suggest
design
vad
full
explor
help
make
decis
ag
load
mode
encapsul
adsorpt
chemic
linkag
mean
impress
find
ag
load
includ
vadss
adjuv
administ
separ
ag
administr
achiev
improv
vaccin
efficaci
instanc
earli
work
show
administr
miner
oilbas
ow
emuls
adjuv
one
week
prior
administr
ag
still
trigger
effect
respons
ag
subcutan
immun
adjuv
quil
alon
ie
without
coinject
ag
also
significantli
expand
antibodi
repertoir
administ
ag
full
activ
innat
immun
system
beforehand
vad
adjuv
may
possibl
prerequisit
mechan
success
immun
ag
via
separ
administr
practic
signific
may
allow
subsequ
immun
even
differ
vaccin
leav
vad
adjuv
unlik
liposom
use
dd
treat
diseas
solid
tumour
agerel
macular
degener
amd
function
via
deliv
drug
activ
target
sick
cell
lesion
liposom
vad
take
action
passiv
target
immun
cell
mean
liposom
vad
captur
immun
cell
includ
apc
patrol
search
alien
materi
throughout
bodi
perform
defens
mission
also
mean
ag
deliv
liposom
possess
great
chanc
pick
immun
cell
whether
still
carri
vad
result
ag
releas
leakag
liposom
seem
make
less
sens
vaccin
thu
may
receiv
concern
vad
develop
enough
dd
reflect
mani
report
wherein
ag
releas
test
complet
neglect
situat
may
exacerb
notic
licens
vaccin
base
vad
function
elicit
immun
pathogen
without
load
ag
carrier
via
encapsul
adsorpt
manufactur
mostli
admix
ag
liposom
np
even
immun
exemplifi
vaccin
suppli
separ
packag
ag
vad
despit
fact
ag
releas
still
one
factor
import
impact
immunostimulatori
activ
liposom
vad
rapid
releas
render
ag
direct
exposur
tissu
fluid
may
possibl
damag
bioactiv
also
wide
cellular
uptak
possibl
apc
sensit
vad
adjuv
thu
lead
compromis
efficaci
vaccin
addit
certain
adjuv
compound
low
molecular
weight
mw
incorpor
liposom
vadss
guarante
codeliveri
ag
popul
apc
avoid
system
distribut
offtarget
cellular
uptak
exampl
resiquimod
small
watersolubl
agonist
endosomeloc
rapidli
distribut
throughout
bodi
inject
aqueou
solut
conjug
cation
liposom
compos
ddatdb
achiev
codeliveri
ag
mous
model
though
bound
combin
significantli
elev
alreadi
strong
adjuvant
cation
liposom
notabl
mani
studi
liposom
vadss
actual
report
ag
releas
data
howev
direct
relationship
ag
releas
featur
induc
immun
qualiti
rare
elucid
moreov
investig
ag
releas
mostli
conduct
vitro
experi
hardli
reflect
real
profil
liposom
manifest
vivo
circumst
vivo
liposom
encount
numer
chemic
protein
enzym
may
select
bind
carrier
possibl
catalys
compon
degrad
even
make
carrier
broken
inde
mani
type
liposom
especi
cation
one
design
vad
load
ag
via
electrostat
attract
inject
bodi
like
neutral
lose
carri
cargo
studi
relev
vivo
characterist
fluoresc
materi
often
employ
label
track
behaviour
liposom
bodi
howev
hardli
provid
strong
evid
verifi
carrier
integr
sinc
fluoresc
materi
may
aggreg
emit
light
even
carrier
collaps
point
even
theoret
analys
sound
reason
experiment
data
vivo
characterist
carrier
yet
shortag
need
provid
solid
support
ration
design
liposom
vadss
liposom
versatil
vad
suit
variou
immun
rout
includ
mainli
four
way
inject
intramuscular
intraderm
subcutan
intraperiton
intraven
inject
topic
administr
cutan
mucos
administr
oral
uptak
inhal
three
reason
drive
research
explor
differ
immun
rout
satisfi
dosag
form
requir
offer
conveni
administr
importantli
improv
efficaci
usual
vaccin
perform
administ
three
site
muscl
mucosa
skin
howev
recent
intraven
inject
iv
mimick
natur
transmiss
process
insect
bite
also
triall
immun
certain
vaccin
special
pathogen
plasmodium
falciparum
pf
mosquitoborn
parasit
caus
maladi
malaria
direct
enter
blood
host
earli
work
nussenzweig
et
al
prove
defens
immun
preerythrocyt
phase
plasmodium
berghei
pb
caus
malaria
certain
rodent
could
achiev
immun
repeat
intraven
inject
xray
irradi
pb
sporozoit
pbspz
earli
research
great
signific
sinc
primarili
pave
way
develop
antimalaria
vaccin
advanc
techniqu
research
recent
engin
novel
malaria
vaccin
compos
radiationattenu
metabol
activ
pfspz
given
nonhuman
primat
via
iv
immun
sc
subcutan
vaccin
trigger
strong
durabl
antipfspz
cell
reaction
peripher
blood
even
potent
liver
prospect
site
immun
protect
suggest
iv
administr
optim
immun
rout
pfspz
vaccin
recent
work
schmidt
et
al
confirm
ip
intraperiton
immun
provok
drainag
vaccin
dln
wherein
activ
resid
dc
ag
cross
present
prerequisit
induct
ctl
respons
comparison
sc
subcutan
im
intramuscular
immun
initi
format
vaccin
depot
administr
site
may
hamper
approach
vaccin
dc
also
wang
group
show
administr
multifunct
liposom
vad
microneedl
array
ma
mous
oral
caviti
mucosa
induc
robust
immun
oral
gastrointestin
mucosa
favour
prophylaxi
pathogen
transmit
via
ingest
rout
comparison
similar
liposom
vad
deliv
ma
administ
mice
via
vagin
mucosa
elicit
strong
immun
reproduct
duct
intestin
lumen
peculiar
signific
defend
sexual
transmit
infect
recent
fox
et
al
develop
leca
agload
pegyl
liposom
contain
two
tlra
gla
administ
intranas
mice
elicit
effici
intestin
mucos
respons
compar
sc
administr
intranas
vaccin
induc
mice
produc
elev
level
fecal
iga
serum
final
provid
protect
mice
diseas
challeng
therefor
immun
rout
addit
physicochem
immunolog
characterist
vad
also
play
key
role
elicit
protect
immun
especi
mucosa
wherebi
pathogen
preferenti
invad
host
taken
togeth
physicochem
properti
liposom
signific
influenc
adjuv
deliveri
efficaci
vad
crucial
influenc
paramet
includ
membran
fluiditi
surfac
charg
pegyl
well
physic
size
play
individu
role
modul
biolog
behaviour
vad
mutual
influenc
ultim
provid
collect
effect
immunostimulatori
activ
thu
liposom
vad
may
show
depot
effect
target
biodistribut
specif
intracellular
traffick
act
combin
dictat
outcom
adapt
immunorespons
result
liposom
formul
optim
full
consider
vast
array
lipid
combin
vesicl
structur
physicochem
characterist
issu
may
well
regard
multifactori
impact
optim
combin
constitut
effect
vad
capabl
deliv
ag
also
promot
apc
activ
interact
downstream
immunocyt
elicit
desir
immun
though
np
exemplifi
strict
sens
liposom
known
despit
carrier
type
size
structur
surfac
properti
ag
releas
featur
main
decis
factor
defin
function
vad
therefor
investig
outcom
conclus
may
provid
use
refer
develop
liposom
vad
well
ultim
goal
develop
vad
make
vaccin
abl
trigger
immun
system
establish
potent
immun
prevent
pathogen
infect
eras
invad
pathogen
cure
harm
lesion
discuss
modul
liposom
physicochem
properti
size
surfac
charg
also
improv
immunostimulatori
effect
howev
case
liposom
specif
engin
certain
way
engend
special
function
enabl
effici
activ
host
immun
system
vertebr
immun
system
accord
function
includ
two
subtyp
innat
immun
system
nk
natur
killer
cell
monocyt
especi
apc
mp
dc
main
particip
adapt
immun
system
b
cell
main
particip
whilst
adapt
immun
system
evolv
around
million
year
confin
vertebr
innat
immun
system
establish
much
longer
time
act
main
defens
strategi
among
vertebr
invertebr
well
plant
modul
rather
conserv
mechan
innat
immun
system
play
import
role
construct
antipathogen
immun
activ
precursor
prerequisit
sponsor
agspecif
adapt
immunorespons
therefor
innat
immunorespons
usual
occur
advanc
upon
detect
pampsdamp
via
variou
prr
tlr
clr
rlr
nlr
commonli
express
immunocyt
especi
apc
notabl
prr
provid
collect
target
design
vad
boost
immunorespons
toward
ag
thu
wide
employ
engin
function
liposom
also
np
vaccin
carrier
molecular
level
liposom
frequent
engin
vad
bear
prra
prr
agonist
effici
target
activ
apc
trigger
proinflammatori
transcript
factor
nuclear
factor
kappalightchainenhanc
activ
b
cell
creb
cyclic
amprespons
elementbind
protein
activ
protein
ifnregulatori
factor
secret
cytokin
chemokin
benefici
promot
innat
adapt
immunorespons
prra
bioactiv
molecul
high
affin
distinct
biomark
apc
surfac
cluster
differenti
also
explor
modifi
liposom
np
constitut
target
vad
elicit
potent
immun
practic
vad
liposom
often
design
target
depot
recruit
bioadhes
effect
sentinel
apc
scatter
affluent
superfici
tissu
skin
mucosa
moreov
liposom
also
engin
target
secondari
lymphoid
organ
immunocyt
dc
mp
fdc
follicular
dc
well
fbc
follicular
b
cell
dens
cluster
within
compartment
dln
spleen
pegyl
size
reduct
gener
stealth
effect
tissu
compon
anoth
strategi
improv
immnunostimulatori
function
liposom
vad
involv
render
carrier
abil
engend
lysosom
escap
allow
deliv
ag
avoid
endolysosom
degrad
lysosom
degrad
prove
common
pathway
wherebi
apc
process
intern
npcarri
ag
small
often
useless
fragment
thu
may
caus
compromis
vaccin
contrast
ag
success
manag
lysosom
escap
enter
cytoplasm
may
handl
like
endogen
ag
proteasom
gener
number
epitop
tend
adher
mhci
present
favour
establish
cellular
immun
liposom
known
possess
lipid
bilay
membran
despit
bear
intrins
instabl
neg
factor
develop
clinic
product
benefici
provid
uniqu
structur
admit
divers
modif
function
materi
differ
mode
surfac
adsorpt
conjug
encapsul
intercal
within
lipid
bilay
render
liposom
multifunct
vad
liposom
may
engin
certain
way
possess
special
function
abl
interven
intracellular
process
improv
efficaci
deliv
vaccin
exampl
liposom
frequent
engin
materi
intrins
specif
adjuvant
squalen
saponin
eg
water
solubl
well
variou
tlra
eg
mpla
cpg
odn
boost
immunorespons
liposom
vad
attract
research
interest
thank
distinct
immuneostimulatori
function
may
summar
follow
rapidli
activ
innat
immun
system
may
ultim
translat
robust
humor
cellular
immun
pathogen
induc
broad
spectrum
adapt
immun
provid
protect
defenc
pathogen
heterovari
exampl
vaccin
carri
mplaincorpor
liposom
could
effect
protect
host
invas
strain
influenza
human
papillomaviru
hpv
bear
antigen
compon
yet
includ
product
boost
immunorespons
efficaci
vaccin
certain
special
recipi
infant
feebl
patient
elderli
incomplet
weaken
immun
system
exampl
includ
market
product
formul
mpla
cpg
odn
andor
protect
popul
hbv
influenza
herp
zoster
viru
advantag
togeth
feasibl
largescal
product
long
record
high
safeti
profil
pave
way
engin
advanc
liposom
vadss
conquer
mani
devast
pathogen
develop
function
mucos
vad
wang
group
prepar
mannosyl
mplamodifi
liposom
mml
stealth
mplamodifi
liposom
sml
fabric
togeth
socal
prosmma
prosmlmllconstitut
microneedl
array
fig
vagin
administr
prosmma
mice
mucos
patch
elicit
robust
antiag
humor
well
cellular
immun
system
mucos
level
especi
reproduct
intestin
tissu
deep
dissect
disclos
novel
vad
engend
liposomecarri
ag
phagocytos
mucos
dlnresid
apc
thereaft
substanti
crosspres
mhci
exposur
result
lysosom
escap
ro
reactiv
oxygen
speci
irrit
caus
function
liposom
lead
establish
ultim
comprehens
intens
immun
result
prove
liposom
versatil
carrier
incorpor
immuneboost
molecul
fabric
administrationfit
devic
like
microneedl
array
form
multifunct
vad
abl
elicit
strong
immun
mucosa
set
first
line
defenc
pathogen
recent
karmakar
et
al
made
lrhamnos
rha
epitopeanchor
liposom
conjug
synthet
glycopeptid
ag
deriv
mucin
overexpress
sever
type
cancer
engin
contain
segment
immunogen
peptid
epitop
expos
immun
system
fig
vivo
experi
demonstr
administ
rhapreimmun
mice
rha
epitopeand
aganchor
liposom
remark
enhanc
product
ctl
well
ab
particular
kind
ab
might
possess
big
potenti
bind
kill
tumour
cell
adcc
ab
depend
cellmedi
cytotox
via
receptor
express
certain
myeloid
cell
nk
cell
mp
neutrophil
eosinophil
author
show
vivo
rhamodifi
liposom
bound
antirha
ab
form
immun
complex
facilit
apc
uptak
cross
present
ag
result
suggest
possibl
use
liposom
vad
enhanc
apc
cross
present
ag
epitop
mhci
abmedi
phagocytosi
via
format
antirhafcr
fc
receptor
fig
occur
owe
presenc
natur
antirha
ab
notabl
human
natur
antirha
ab
exist
abundantli
igm
mice
gener
bind
poorli
thu
exert
trivial
inhibitori
effect
adccbas
anticanc
activ
desir
make
vad
use
tempor
monitor
immunorespons
includ
activ
state
immun
cell
popul
resid
within
tissu
meanwhil
well
perform
immun
process
concept
vad
signific
regard
sever
issu
involv
vaccin
immun
reaction
supervis
efficaci
evalu
regim
regul
immun
complianc
recent
irvin
group
creat
novel
vad
bear
concept
fabric
polyllactideconstruct
microneedl
array
microneedl
project
coat
mixtur
agcpg
adjuv
load
liposom
interbilay
crosslink
multilamellar
vesicl
icmv
ca
crosslink
algin
polym
form
stimulatori
sampl
microneedl
ssmn
insert
skin
ssmn
polym
swell
due
hydrat
porou
matrix
capabl
longitudin
sampl
interstiti
fluid
infiltr
local
leukocyt
enabl
parallel
monitor
immun
reaction
caus
trivial
injuri
fig
mice
even
antiag
cell
system
circul
could
detect
convent
protocol
ssmn
still
success
sampl
tissueresid
memori
cell
skin
exert
influenc
immun
statu
antigenexpos
anim
model
could
liposomeconstruct
ssmn
success
adapt
accomplish
vaccin
regim
tempor
monitor
immunocyt
collect
immunolog
inform
skin
mucos
tissu
noninvas
manner
would
repres
superior
function
vad
summari
immun
system
mammal
equip
numer
compet
compon
variou
leukocyt
subset
cell
receptor
cytokin
chemokin
compliment
tightli
link
complex
integr
compon
orchestr
exquisit
fulfil
defens
function
also
provid
multipl
target
design
function
liposom
vad
modul
individu
compon
may
significantli
affect
whole
commun
signal
pathway
involv
immunorespons
biolog
process
also
prove
feasibl
multipl
immun
compon
target
simultan
multifunct
liposom
custom
vad
abl
effect
boost
immun
pathogen
liposom
suitabl
api
activ
pharmaceut
ingredi
carrier
possess
numer
advantag
includ
easi
largescal
prepar
mention
howev
took
rather
long
time
make
first
drugload
liposom
ever
come
clinic
product
bit
discourag
far
beyond
commit
liposom
scientist
especi
middl
research
even
doubt
feasibl
liposom
dd
fortun
time
certain
liposomebas
cosmet
product
success
brought
market
sever
giant
fashionfocus
compani
hope
never
helpless
pharmaceut
scientist
see
first
batch
liposom
product
flamboyantli
market
antiag
cream
exagger
name
captur
introduc
dior
follow
immedi
niosom
market
lancom
loreal
compani
encourag
combin
great
achiev
optim
liposom
formul
control
vesicl
size
lyophilis
stabl
dri
product
disaccharid
lyoprotect
scientist
eventu
brought
european
market
first
therapeut
liposom
product
amphotericin
bload
suv
optim
formul
hspcchodspgamphotericin
b
mole
ratio
size
around
nm
later
author
usa
treat
system
fungal
infect
certain
protozoan
infect
viscer
leishmaniasi
primari
amoeb
meningoenceph
meanwhil
two
breakthrough
techniqu
remot
load
drug
liposom
pegyl
liposom
surfac
achiev
matur
clear
develop
liposom
product
longstand
crucial
barrier
includ
poor
encapsul
drug
instabl
aqueou
suspens
liposom
short
circul
time
vivo
liposom
due
rapid
remov
conduct
mononuclear
phagocyt
system
mp
system
inject
consequ
achiev
first
anticanc
liposom
drug
pegyl
liposom
compos
hspcchodspempeg
mass
ratio
size
nm
load
ammonium
sulfategradi
procedur
doxorubicin
total
lipiddrug
mass
ratio
came
ultim
market
final
approv
fda
treatment
aidsrel
kaposi
sarcoma
later
expand
therapi
ovarian
cancer
multipl
myeloma
april
worldwid
liposom
product
ever
enter
market
treatment
variou
diseas
includ
infect
pain
mostli
tumour
list
tabl
notabl
among
approv
liposom
product
liposom
vadsbas
vaccin
author
prophylaxi
pathogen
infect
healthi
popul
epax
inflex
administ
intramuscularli
defend
hepat
viru
season
influenza
viru
respect
nasalflu
given
uniqu
intranas
spray
also
influenza
viru
unfortun
withdrawn
market
shortli
approv
due
caus
bell
palsi
facial
paralysi
recipi
approv
liposom
vaccin
well
introduc
elsewher
herein
newli
author
vaccin
present
bit
detail
stateoftheart
liposom
vadsbas
novel
subunit
vaccin
develop
pharmaceut
giant
gsk
glaxosmithklin
approv
octob
us
fda
prophylaxi
elderli
age
year
older
shingl
herp
zoster
hz
shingl
caus
reactiv
dormant
dna
vzv
varicella
zoster
viru
member
herpesviru
famili
resid
sensori
dorsal
root
ganglia
first
infect
host
like
caus
rel
mild
varicella
also
call
chickenpox
fig
primari
infect
trigger
respons
vzv
lead
releas
antivir
cytokin
activ
nk
cell
usual
abl
control
viral
replic
mucosa
also
primari
infect
stimul
host
establish
adapt
memori
immun
form
persist
antivzv
igg
vzvspecif
cell
particularli
ctl
kind
immun
correl
best
sever
primari
infect
prevent
reactiv
latent
vzv
resid
ganglion
cell
unfortun
natur
wane
time
allow
possibl
occurr
shingl
late
life
shingl
may
caus
risk
factor
includ
old
age
weaken
cellular
immun
ill
femal
gender
genet
suscept
mechan
trauma
recent
psycholog
stress
white
race
shingl
usual
manifest
prodrom
acut
neuralgia
day
preced
rash
accompani
potenti
devast
complic
secondari
bacteri
infect
sepsi
meningoenceph
visual
hear
impair
fact
liveattenu
vaccin
hz
alreadi
licens
mercksanofi
pasteur
adult
year
age
price
singl
dose
regim
effect
reduc
incid
complic
shingl
howev
vaccin
efficaci
decreas
rapidli
time
incid
shingl
may
return
around
baselin
level
around
year
post
vaccin
moreov
certain
contraind
liveattenu
microbebas
vaccin
eg
vzv
naiv
immunosuppress
patient
vaccin
may
caus
diseas
suggest
desir
develop
altern
subunit
vaccin
good
safeti
profil
high
efficaci
issu
repres
guidanc
impetu
design
develop
novel
vaccin
shingl
thu
come
antihz
subunit
vaccin
base
liposom
vad
provid
two
part
vad
freezedri
powder
recombin
vzv
glycoprotein
e
ge
ag
vad
consist
aqueou
suspens
dopcchompla
liposom
size
nm
bound
liposom
cho
fig
ag
ge
abund
glycoprotein
vzv
virion
cell
infect
vzv
play
crucial
role
viru
replic
celltocel
spread
elicit
greater
immun
respons
glycoprotein
antigen
accomplish
clinic
trial
confirm
vaccin
efficaci
prevent
develop
shingl
year
follow
overal
subject
older
year
age
around
particip
older
year
old
importantli
antiag
respons
appear
preserv
age
sinc
protect
efficaci
wane
minim
year
well
maintain
adult
age
year
ration
design
attribut
sever
aspect
strong
background
studi
result
right
choic
proper
ag
ge
compon
guarante
effect
activ
innat
immunorespons
mplaliposom
direct
respons
toward
pathway
via
trigger
lead
robust
cellular
immun
liposom
vad
high
stabil
signific
success
vaccin
liposom
field
lie
firmli
demonstr
subunit
vaccin
possess
good
safeti
profil
also
potenti
elicit
antipathogen
immun
stronger
whole
microbebas
tradit
vaccin
long
ration
formul
suitabl
vad
base
appropri
nanocarri
liposom
decad
develop
liposom
success
employ
dd
vad
variou
clinic
therapi
focus
mainli
treatment
cancer
vaccin
infecti
diseas
list
tabl
particular
liposom
vad
easili
decor
variou
immuneboost
molecul
thu
capabl
remark
improv
efficaci
subunit
vaccin
even
surpass
convent
whole
microbebas
vaccin
alway
concern
revers
virul
caus
sever
complic
vadss
base
metal
gold
silver
iron
np
inorgan
silica
np
polymer
np
though
also
show
advantag
convent
formul
fulfil
function
deliveri
adjuv
mostli
earli
develop
emulsionbas
vad
approv
novarti
deliveri
influenza
vaccin
defin
formul
consist
ow
emuls
later
reformul
gsk
emuls
tween
known
howev
unlik
liposom
emuls
fact
fragil
carrier
limit
capac
allow
surfac
modif
function
materi
target
molecul
form
divers
vad
deliv
subunit
vaccin
alum
anoth
strong
vad
use
nearli
centuri
enhanc
antibodi
immun
unfortun
often
fail
elicit
effect
cellular
immun
show
drawback
reactogen
associ
unwant
inflammatori
side
effect
moreov
alum
alway
provid
shelter
labil
ingredi
may
undermin
quaternari
tertiari
structur
protein
due
potent
phosphophil
exert
strong
bind
protein
phosphoru
group
contrast
liposom
easili
engin
possess
benefici
featur
effect
vad
deliveri
ag
show
good
biocompat
minim
side
effect
prospect
liposom
may
formul
advanc
vad
suitabl
develop
efficaci
vaccin
combat
mani
tediou
pathogen
especi
challeng
one
hiv
hcv
hsv
even
emerg
super
bug
futur
liposom
may
develop
play
role
versatil
vad
mimic
way
wherebi
ag
maintain
expos
apc
pathogen
natur
infect
trigger
strong
immunorespons
achiev
requir
liposom
structur
keep
ag
natur
present
possibl
embed
multipl
copi
peptid
ag
render
ag
resist
environment
violat
aspect
may
emphas
improv
immunostimulatori
function
liposom
may
involv
act
depot
increas
exposur
time
ag
immun
cell
enhanc
apc
uptak
vaccin
target
immunocyt
lymph
node
save
ag
fit
mucos
vaccin
set
system
mucos
immun
render
ag
lysosom
escap
facilit
crosspresent
ag
via
mhci
present
establish
cellular
immun
eras
cellhidden
pathogen
tumour
cell
notabl
function
engend
lysosom
escap
enhanc
ag
cross
present
control
immunolog
express
specif
pathway
hardli
obtain
unless
relat
intracellular
biolog
featur
fulli
understood
abl
explor
test
activ
vad
tailor
correspond
function
respons
environment
stimulu
sens
physiolog
factor
target
intracellular
structur
also
numer
question
still
remain
open
regard
develop
liposom
vad
produc
clinic
product
open
question
may
list
call
attent
consider
research
commit
make
liposom
vaccin
also
list
common
issu
still
exist
bottleneck
translat
laboratori
work
liposom
vad
clinic
applic
often
ignor
research
first
safeti
put
forward
front
rank
given
novel
liposom
incorpor
synthet
materi
may
possibl
gener
potenti
cytotox
vivo
moreov
novel
liposom
vadss
long
record
safeti
profil
even
anim
model
let
alon
human
use
leav
open
question
toxic
fulli
address
accept
altern
method
deliv
novel
human
vaccin
second
stabil
anoth
outstand
concern
consid
liposom
colloid
system
though
conquer
aggreg
instabl
pegyl
lyophil
often
custom
function
materi
especi
environmentsensit
one
render
carrier
unendur
longterm
storag
third
scaleup
product
liposom
subject
fig
schemat
descript
liposomebas
vad
use
boost
efficaci
subunit
vaccin
vzv
varicella
zoster
viru
contain
ag
ge
reprint
littl
adapt
permiss
refer
sever
level
modif
practic
difficulti
complex
procedur
mani
step
may
make
inconsist
batchtobatch
product
meanwhil
modif
expens
materi
may
enhanc
product
cost
complet
unaccept
level
repres
anoth
problem
fourth
translat
efficaci
novel
liposom
vad
anim
studi
human
trial
confront
also
mani
obstacl
present
variou
type
liposom
vadss
elabor
design
present
promis
outcom
immuneboost
activ
unfortun
murin
small
anim
model
may
yet
inappropri
one
specif
vaccin
case
yet
impract
directli
interpret
result
studi
document
rodent
clinic
refer
wherea
solid
conclus
drawn
investig
use
differ
anim
model
pig
rhesu
monkey
even
chimpanze
often
lack
studi
novel
liposom
vad
fifth
preval
low
reproduc
current
publish
outcom
especi
drug
develop
field
result
inappropri
design
littl
practic
ration
combin
posit
resultori
publish
bia
misconcept
research
public
set
also
huge
barrier
translat
bench
work
bed
therapi
notabl
unreproduc
result
caus
substanti
wast
valuabl
resourc
also
badli
discourag
industri
partner
devot
translat
find
research
academia
circl
although
reproduc
publish
result
liposom
vadss
remain
unclear
realiti
hardli
optimist
base
disappoint
outcom
investig
perform
drug
develop
field
concern
also
indirectli
reflect
profession
comment
certain
public
complain
difficulti
interpret
report
result
also
disturb
aris
observ
contradict
print
outcom
obvious
kind
side
effect
aris
develop
vaccin
even
base
liposom
vad
claim
high
safeti
profil
liposom
still
extens
employ
effici
carrier
deliv
vaccin
owe
benefici
properti
high
safeti
big
load
capac
easi
prepar
decor
engend
multipl
function
particular
incorpor
function
molecul
ligand
tlr
adjuvanticitybear
chemic
liposom
actual
act
versatil
vad
greatli
enhanc
immun
induc
carri
vaccin
research
continu
commit
effort
develop
optim
formul
combin
emerg
novel
materi
inspir
deep
understand
process
involv
immunolog
reaction
trigger
vaccin
numer
problem
barrier
develop
function
liposom
vadss
handl
result
mani
novel
vaccin
base
liposom
vad
eventu
produc
clinic
immun
conquer
varieti
lifethreaten
diseas
